Adagene Inc Revenue Growth Rates (ADAG), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Adagene Inc   (NASDAQ: ADAG)
 

ADAG's Revenue Growth by Quarter and Year

Adagene Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADAG Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 7.67
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 7.67

ADAGs Annual Revenue
Adagene Inc 's Revenue in the fiscal year 2025 $ 7.67 millions
Adagene Inc 's Revenue in the fiscal year 2024 $ 0.10 millions
Adagene Inc 's Revenue in the fiscal year 2023 $ 18.11 millions
Adagene Inc 's Revenue in the fiscal year 2022 $ 9.29 millions
Adagene Inc 's Revenue in the fiscal year 2021 $ 10.18 millions




ADAG Revenue fourth quarter 2025 Y/Y Growth Comment
Adagene Inc achieved in the fourth quarter 2025, above Company average Revenue surge of 7570.9% year on year, to $ 7.67 millions.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 25 other companies have achieved higher Revenue growth. While Adagene Inc ' s Revenue doubling of 7570.9% ranks overall at the positon no. 129 in the fourth quarter 2025.


ADAG Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 7570.9 % -99.45 % 94.94 % -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   7570.9 % -99.45 % 94.94 % -

Financial Statements
Adagene Inc 's fourth quarter 2025 Revenue $ 7.67 millions ADAG's Income Statement
Adagene Inc 's fourth quarter 2024 Revenue $ 0.10 millions Quarterly ADAG's Income Statement


ADAG Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   7570.9 % -99.45 % 94.94 % -


Back to ADAG Growth rate Comparisons >> Back to ADAG Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #47
Overall #129

Revenue Y/Y Growth Statistics
High Average Low
94.9 % -2.27 % -99.43 %
(Dec 31 2023)   (Dec 31 2024)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #47
Overall #129
Revenue Y/Y Growth Statistics
High Average Low
94.9 % -2.27 % -99.43 %
(Dec 31 2023)   (Dec 31 2024)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Adagene Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ADAG's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ADAG's IV. Quarter Q/Q Revenue Comment


Adagene Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 7.67 $ 0.10 $ 18.11 $ 9.29 $ 10.18
Y / Y Revenue Growth (TTM) 7332.76 % -99.43 % 94.9 % -8.67 % 1351.75 %
Year on Year Revenue Growth Overall Ranking # 129 # 107 # 0 # 156 # 0
Seqeuential Revenue Change (TTM) 7332.76 % -99.43 % 94.9 % -8.67 % 1351.75 %
Seq. Revenue Growth (TTM) Overall Ranking # 129 # 107 # 0 # 156 # 0


Cumulative Revenue growth Comment
Adagene Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 7332.76% year on year, to $ 8 millions if the fiscal year would have ended in Dec 31 2025.
Adagene Inc 's trailing twelve months Revenue growth was higher than company's average -2.27% and higher than -99.43% growth in Dec 31 2024.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 7332.76 % increase from $0.1 millions in the period from Dec 31 2024 to Dec 31 2021.

In the Healthcare sector 46 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 107 to 129.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 26
Healthcare Sector # 47
Overall # 129

Revenue TTM Y/Y Growth Statistics
High Average Low
94.9 %
 -2.27 %
-99.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 47
S&P 500 # 129
Cumulative Revenue growth Comment
Adagene Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 7332.76% year on year, to $ 8 millions if the fiscal year would have ended in Dec 31 2025.
Adagene Inc 's trailing twelve months Revenue growth was higher than company's average -2.27% and higher than -99.43% growth in Dec 31 2024.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 7332.76 % increase from $0.1 millions in the period from Dec 31 2024 to Dec 31 2021.

In the Healthcare sector 46 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 107 to 129.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 26
Healthcare Sector # 47
Overall # 129

Revenue TTM Y/Y Growth Statistics
High Average Low
94.9 %
-2.27 %
-99.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 47
S&P 500 # 129




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ADAG's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Orchestra Biomed Holdings Inc 12,120.16%$ 12,120.158 millions
Septerna Inc 11,276.42%$ 11,276.415 millions
Rallybio Corporation11,000.00%$ 11,000.000 millions
Arrowhead Pharmaceuticals Inc 10,461.32%$ 10,461.320 millions
Adagene Inc 7,332.76%$ 7,332.756 millions
Ainos Inc 6,937.97%$ 6,937.975 millions
Precision Biosciences Inc5,261.13%$ 5,261.129 millions


About Adagene Inc Revenue Growth Rates (ADAG), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Adagene Inc (CIK 1818838).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-038612
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Adagene Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.